Genpharmasec Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24231MH1992PLC323914 Incorporated 16 November 1992 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - BSE: 531592 Public Limited Company pharma MSME · Medium
Market Cap
₹59.80 Cr
GENPHARMA · BSE
Share Price
₹1.05
-2.78% today
Revenue
₹140 Cr
FY 2025-26 · +315.0% YoY
EBITDA
₹1.22 Cr
Margin 0.9%
Net Profit
₹1.60 Cr
FY 2025-26 · +31.2% YoY
P/E (TTM)
27.6x
P/B 0.9x
ROE
0.8%
ROCE 2.5%
Debt / Equity
0.31
Interest cover -129.2x

About Genpharmasec Limited

Data last updated:

Genpharmasec Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 16 November 1992 and has been in existence for over 34 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24231MH1992PLC323914. Its GSTIN is 27AABCA8318D2ZX (Maharashtra). The company holds 2 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 531592.

The company has an authorised share capital of ₹56 Cr and a paid-up capital of ₹55.37 Cr. It was formerly known as Generic Pharmasec Limited and Adi Rasayan Limited. It is led by directors including Sohan Chaturvedi (Whole-Time Director) and Mayur Bharatbhai Bhatt.

Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Mumbai, Maharashtra.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹139.94 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹1.6 Cr (net margin 1.1%) and EBITDA of ₹1.22 Cr (EBITDA margin 0.9%). The net worth stands at ₹66.26 Cr (up 1.7% YoY). Total assets are valued at ₹100.73 Cr (up 42.7% YoY).

The company is associated with 1 brand: Genpharmasec. As per MCA filings, the company has open charges of ₹12.5 Cr and satisfied charges of ₹30.35 Cr on record. Court records list 6 cases involving the company, including 1 filed by the company and 5 filed against it. The company has 48 deals on record (47 market trades, 1 funding round), with disclosed funding of ₹48.45 Cr; the latest was in August 2026. Its 3 peer companies in the BFSI industry (Broking Services, Healthcare Equipment Retail and Distribution), with the same principal business activity (wholesale trading) are compared by revenue, 2 larger and 1 smaller; the largest is Imaging Products (India) Private Limited with revenue of ₹36.97 Cr. The company has 1 MSME Form 1 return on record for the period ending Sep 2019, listing 2 overdue payments to 1 micro and small supplier.

Genpharmasec Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-18-0208449). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website genpharmasec.com.

Company details

CIN L24231MH1992PLC323914
Registration Number 323914
Incorporation Date 16 November 1992
ROC Mumbai
Listing Status Listed - Listed on BSE (531592)
Company Status Active
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-MH-18-0208449

Name history

Genpharmasec has undergone 3 name changes throughout its history. The company was previously known as Generic Pharmasec Limited, Adi Rasayan Limited, and Sun Face Pharmasec Limited. The current legal name is Genpharmasec Limited.

Company NameStatus
Genpharmasec LimitedCurrent
Generic Pharmasec LimitedPrevious
Adi Rasayan LimitedPrevious
Sun Face Pharmasec LimitedPrevious

CIN history

Genpharmasec has one previous CIN (Corporate Identification Number): L24231GJ1992PLC018572. The current CIN is L24231MH1992PLC323914, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24231MH1992PLC323914Current
L24231GJ1992PLC018572Previous

Recognitions & Rankings of Genpharmasec

MSME (Udyam registered) Ministry of MSME
Category
Medium (2026-27)
Udyam number
UDYAM-MH-18-0208449

Contact details

Genpharmasec Limited's registered office is in Mumbai, Maharashtra. Its website is genpharmasec.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Registered Address
    Office No. 104 & 105 1st Floor Gundecha Industrial Premises Co – Op Soc. Ltd.Akurli Road Kand, Ivali East, Mumbai, Maharashtra, India – 400101
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Genpharmasec Limited, buy the company report.

Comprehensive company report
Genpharmasec Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Genpharmasec operates one associated brand: Genpharmasec. Each brand links to its own profile.

BrandDescriptionWebsite
Pharmaceutical products and services are provided and distributed.genpharmasec.com

Business activity

The main business activity of Genpharmasec is trade. In detail, this covers wholesale trading.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
GTradeG1Wholesale Trading

To see the full business activity and turnover split of Genpharmasec Limited, buy the company report.

Financials of Genpharmasec Limited

FY 2025-26 filings available

Genpharmasec Limited reported revenue of ₹139.94 Cr (up 315% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹140 Cr
+315.0% YoY
EBITDA
₹1.22 Cr
+1642.9% YoY
Profit After Tax
₹1.60 Cr
+31.1% YoY
Net Worth
₹66.26 Cr
+1.7% YoY
Total Assets
₹101 Cr
+42.7% YoY
Total Debt
₹34.95 Cr
+561.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Income statement
Revenue14033.7230.4125.52
Revenue growth+315.0%+10.9%+19.2%-
EBITDA1.220.070.060.26
EBITDA margin+0.9%+0.2%+0.2%+1.0%
Profit before tax0.971.870.270.28
Net profit1.601.22(0.15)1.12
Net profit margin+1.1%+3.6%-0.5%+4.4%
EPS (₹)0.010.020.000.04
Balance sheet
Total assets10170.5768.4218.41
Net worth66.2665.1664.3915.33
Total debt34.955.283.893.08
Cash & bank10.075.2718.831.99
Net working capital43.1017.1136.5816.51
Cash flow
Cash from operations(17.55)2.95(2.95)(3.06)
Cash from investing13.26(4.22)(28.06)0.36
Cash from financing3.92(1.25)47.853.08
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue85.6649.7155.4339.8332.6412.0414.018.48
Revenue growth (YoY)+162.4%+312.9%+295.7%+369.7%+441.3%+131.5%--
Other income1.060.371.020.980.460.690.940.81
EBITDA1.640.961.99(1.24)(0.47)0.94(1.00)0.71
EBITDA margin+1.9%+1.9%+3.6%-3.1%-1.4%+7.8%-7.1%+8.4%
Depreciation0.680.670.680.670.560.270.260.10
Interest0.440.400.480.410.230.120.110.16
Profit before tax1.580.261.85(1.34)(0.80)1.24(0.43)1.26
Tax0.550.430.50(0.50)0.380.03(0.16)0.51
Net profit1.03(0.17)1.35(0.84)(1.18)1.21(0.27)0.75
EPS (₹)0.010.000.02(0.02)(0.02)0.02(0.01)0.01
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue13132.9630.4125.5227.3221.3116.50
Revenue growth+298.5%+8.4%+19.2%-6.6%+28.2%+29.2%-
EBITDA2.420.440.180.26(0.51)1.190.64
EBITDA margin+1.8%+1.3%+0.6%+1.0%-1.9%+5.6%+3.9%
Profit before tax6.443.450.490.28(0.43)1.511.20
Net profit5.462.470.071.12(0.20)1.261.00
Net profit margin+4.2%+7.5%+0.2%+4.4%-0.7%+5.9%+6.1%
EPS (₹)0.100.040.000.04(0.01)0.050.05
Balance sheet
Total assets76.5469.9867.7818.4115.3720.6619.03
Net worth71.4966.5564.5715.3315.3720.6719.04
Total debt4.983.433.213.080.000.000.00
Cash & bank9.295.1418.581.991.613.532.58
Net working capital28.2717.8235.6516.5112.8211.957.87
Cash flow
Cash from operations1.930.96(2.27)(3.06)(2.34)(2.13)1.39
Cash from investing(1.64)(2.92)(29.03)0.360.42(1.41)(4.01)
Cash from financing(0.02)(0.44)47.893.080.004.500.00
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue50.8344.7851.6636.0131.5612.1113.568.34
Revenue growth (YoY)+61.1%+269.8%+281.0%+331.8%+447.0%+128.5%--
Other income1.660.971.621.431.000.821.060.93
Total expenses49.1843.4350.0836.6831.0611.1114.557.40
EBITDA1.651.351.58(0.67)0.501.00(0.99)0.94
EBITDA margin+3.2%+3.0%+3.1%-1.9%+1.6%+8.3%-7.3%+11.3%
Depreciation0.100.100.090.070.040.040.040.05
Interest0.160.130.250.190.080.080.060.11
Profit before tax3.052.092.860.501.381.70(0.03)1.71
Tax0.490.530.55(0.27)0.570.150.200.61

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 19 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue85.6649.7155.4339.8332.6412.0414.018.48
Revenue growth (YoY)+162.4%+312.9%+295.7%+369.7%+441.3%+131.5%--
Other income1.060.371.020.980.460.690.940.81
EBITDA1.640.961.99(1.24)(0.47)0.94(1.00)0.71
EBITDA margin+1.9%+1.9%+3.6%-3.1%-1.4%+7.8%-7.1%+8.4%
Depreciation0.680.670.680.670.560.270.260.10
Interest0.440.400.480.410.230.120.110.16
Profit before tax1.580.261.85(1.34)(0.80)1.24(0.43)1.26
Tax0.550.430.50(0.50)0.380.03(0.16)0.51
Net profit1.03(0.17)1.35(0.84)(1.18)1.21(0.27)0.75
EPS (₹)0.010.000.02(0.02)(0.02)0.02(0.01)0.01
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Revenue14033.7230.4125.52
Revenue growth+315.0%+10.9%+19.2%-
Other income3.163.060.660.10
Total expenses13933.6530.3525.26
Employee cost0.000.990.760.54
EBITDA1.220.070.060.26
EBITDA margin+0.9%+0.2%+0.2%+1.0%
Depreciation2.170.810.040.02
Interest1.240.450.410.06
Profit before tax0.971.870.270.28
Tax0.410.650.42(0.84)
Net profit1.601.22(0.15)1.12
Net profit margin+1.1%+3.6%-0.5%+4.4%
EPS (₹)0.010.020.000.04
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Equity & liabilities
Share capital55.3755.3755.3727.69
Reserves & surplus10.899.799.02(12.36)
Shareholders' funds (net worth)66.2665.1664.3915.33
Minority interest(0.62)0.120.140.00
Secured loans1.080.000.000.00
Unsecured loans33.875.283.893.08
Total debt34.955.283.893.08
Total liabilities10170.5768.4218.41
Assets
Gross block47.848.480.930.15
Net block41.257.590.830.10
Capital work in progress0.000.000.000.00
Investments1.5819.7319.320.95
Inventories13.887.308.849.68
Sundry debtors29.2713.609.105.71
Cash & bank balances10.075.2718.831.99
Loans & advances27.300.252.510.59
Total current assets80.5226.4239.2817.97
Total current liabilities37.429.312.701.46
Net working capital43.1017.1136.5816.51
Total assets10170.5768.4218.41
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Opening cash1.343.171.991.61
Net cash from operating activities(17.55)2.95(2.95)(3.06)
Net cash from investing activities13.26(4.22)(28.06)0.36
Net cash from financing activities3.92(1.25)47.853.08
Net change in cash(0.37)(2.52)16.840.39
Closing cash10.075.2718.831.99
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Growth
Sales growth+315.0%+10.9%+19.2%-
EBITDA growth+1642.9%+16.7%-76.9%-
PBT growth-56.8%+722.2%-3.6%+9997.0%
Net income growth+31.2%+913.3%-113.4%-
Revenue CAGR (3Y)+76.3%---
EBITDA CAGR (3Y)+67.0%---
Profitability & leverage
Net income margin+0.4%+4.7%-0.5%+4.4%
Return on capital employed+2.5%+3.7%0.0%+1.5%
Return on net worth+0.8%+2.4%0.0%+5.6%
Debt / equity0.310.070.090.20
Long-term debt / equity0.230.070.080.16
Interest cover-129.17-104.882,050.0025.00
Efficiency & per share
Fixed asset turnover4.977.1756.31170.13
Inventory turnover13.214.183.282.64
Debtors turnover6.532.974.114.47
EPS (₹)0.030.030.000.04
Dividend per share (₹)0.000.000.000.00
Book value per share (₹)1.201.181.160.55
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue50.8344.7851.6636.0131.5612.1113.568.34
Revenue growth (YoY)+61.1%+269.8%+281.0%+331.8%+447.0%+128.5%--
Other income1.660.971.621.431.000.821.060.93
Total expenses49.1843.4350.0836.6831.0611.1114.557.40
EBITDA1.651.351.58(0.67)0.501.00(0.99)0.94
EBITDA margin+3.2%+3.0%+3.1%-1.9%+1.6%+8.3%-7.3%+11.3%
Depreciation0.100.100.090.070.040.040.040.05
Interest0.160.130.250.190.080.080.060.11
Profit before tax3.052.092.860.501.381.70(0.03)1.71
Tax0.490.530.55(0.27)0.570.150.200.61
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue13132.9630.4125.5227.3221.3116.50
Revenue growth+298.5%+8.4%+19.2%-6.6%+28.2%+29.2%-
Other income4.873.430.720.100.090.330.56
Total expenses12932.5230.2325.2627.8320.1215.86
Employee cost0.000.670.760.540.250.190.13
EBITDA2.420.440.180.26(0.51)1.190.64
EBITDA margin+1.8%+1.3%+0.6%+1.0%-1.9%+5.6%+3.9%
Depreciation0.260.130.020.020.010.010.00
Interest0.590.290.390.060.000.000.00
Profit before tax6.443.450.490.28(0.43)1.511.20
Tax0.980.980.42(0.84)(0.23)0.250.20
Net profit5.462.470.071.12(0.20)1.261.00
Net profit margin+4.2%+7.5%+0.2%+4.4%-0.7%+5.9%+6.1%
EPS (₹)0.100.040.000.04(0.01)0.050.05
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital55.3755.3755.3727.6927.6927.6921.69
Reserves & surplus16.1211.189.20(12.36)(12.32)(7.02)(4.15)
Shareholders' funds (net worth)71.4966.5564.5715.3315.3720.6719.04
Secured loans0.000.000.000.000.000.000.00
Unsecured loans4.983.433.213.080.000.000.00
Total debt4.983.433.213.080.000.000.00
Total liabilities76.5469.9867.7818.4115.3720.6619.03
Assets
Gross block1.240.450.170.150.140.070.05
Net block1.130.360.100.100.110.050.04
Capital work in progress0.000.000.000.000.000.000.00
Investments21.6720.8419.520.952.457.815.76
Inventories12.587.248.849.689.897.683.46
Sundry debtors28.0213.399.105.716.457.527.03
Cash & bank balances9.295.1418.581.991.613.532.58
Loans & advances11.891.161.830.591.150.380.53
Total current assets61.7826.9338.3517.9719.1019.1113.60
Total current liabilities33.519.112.701.466.287.165.73
Net working capital28.2717.8235.6516.5112.8211.957.87
Total assets76.5469.9867.7818.4115.3720.6619.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.522.921.991.613.532.585.20
Net cash from operating activities1.930.96(2.27)(3.06)(2.34)(2.13)1.39
Net cash from investing activities(1.64)(2.92)(29.03)0.360.42(1.41)(4.01)
Net cash from financing activities(0.02)(0.44)47.893.080.004.500.00
Net change in cash0.27(2.39)16.590.39(1.93)0.96(2.62)
Closing cash9.295.1418.581.991.613.532.58
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+298.5%+8.4%+19.2%-6.6%+28.2%+29.2%-
EBITDA growth+450.0%+144.4%-30.8%+151.0%-142.9%+85.9%-
PBT growth+70.6%+669.4%+75.0%+9998.0%-+25.8%+328.6%
Net income growth+121.1%+3428.6%-93.8%+660.0%-115.9%+26.0%-
Revenue CAGR (3Y)+72.7%+6.5%+12.6%+15.7%+315.8%+543.4%+225.2%
EBITDA CAGR (3Y)+110.1%--46.7%-25.9%+78.3%--
Profitability & leverage
Net income margin+4.2%+8.5%+0.2%+4.4%-0.7%+5.9%+6.1%
Return on capital employed+9.5%+5.6%+1.8%+1.8%0.0%+7.6%+5.8%
Return on net worth+7.8%+4.1%+0.1%+6.4%0.0%+6.4%+4.9%
Debt / equity0.060.050.080.100.000.000.00
Long-term debt / equity0.060.050.070.080.000.000.00
Interest cover27.4445.16243.7525.000.000.000.00
Efficiency & per share
Fixed asset turnover155.44106.32190.06176.00260.19355.17550.00
Inventory turnover13.254.103.282.613.113.839.54
Debtors turnover6.342.934.114.203.912.934.67
EPS (₹)0.100.050.000.04(0.01)0.050.05
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)1.291.201.170.550.560.750.81

To see the full year-wise statements and ratios of Genpharmasec Limited, buy the company report.

Board of directors and KMP of Genpharmasec Limited

Genpharmasec Limited currently reports 6 directors and 1 key managerial person. 18 former directors have served the organization.

Current Directors and KMP
NameDesignationAppointment DateTenureStatus
Mayur Bharatbhai BhattDirector01 Nov 20224 Years 0 MonthsCurrent
Sachin Prakash AphandkarDirector01 Nov 20224 Years 0 MonthsCurrent
Hardik Pravinbhai MakwanaCompany Secretary27 Mar 20242 Years 7 MonthsCurrent
Siddhesh Shankar ShendeDirector04 Jul 20224 Years 4 MonthsCurrent
Sohan ChaturvediWhole-Time Director26 Apr 20242 Years 6 MonthsCurrent
Rajesh Mirchumal SadhwaniDirector02 Jan 20197 Years 10 MonthsCurrent
Showing 6 of 7 current directors and KMP. View all directors and KMP

Peer comparison

Genpharmasec Limited is compared with the 3 companies closest to it by revenue in the BFSI industry (Broking Services, Healthcare Equipment Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Genpharmasec Limitedthis company₹139.94 Cr (FY 2026)₹1.6 Cr1.1%315.0%Mumbai, Maharashtra, India
Imaging Products (India) Private Limited₹36.97 Cr (FY 2024)-6.0%Chennai, Tamil Nadu, India
Nexnos Pharma Limited₹36.91 Cr (FY 2025)187.0%Chittorgarh, Rajasthan, India
Mamta Hygiene Products Private Limited₹36.68 Cr (FY 2025)76.0%Gulabpura, Rajasthan, India

To see the full peer comparison of Genpharmasec Limited, buy the company report.

Auditor

Genpharmasec Limited is audited by Abhishek S Tiwari & Associates for the financial year 2023.

Auditor firmFinancial yearFirm registration number
Abhishek S Tiwari & AssociatesFY 2023141048W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 30.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 70.00%.

Promoters: 30.00%Retail & Others: 70.00%
Sep 2026
QUARTER
30.00% Promoters
70.00% Retail & Others
Promoter holding - history
Now 30.00% · Sep 2026High 30.00% · Dec 2025Low 30.00% · Dec 2025
29%29.5%30%30.5%31%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 30.00%Mar 2026: 30.00%Jun 2026: 30.00%Sep 2026: 30.00%30.00%30.00%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters30.00%30.00%30.00%30.00%
Public70.00%70.00%70.00%70.00%

Charges & borrowings

Open charges
₹12.5 Cr
Satisfied charges
₹30.35 Cr
Breakdown by lending institutions
Hdfc Bank Limited₹10.00 Cr
Others₹2.50 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
20 Dec 2025101210453Hdfc Bank Limited₹10 CrOpen
06 May 2025101108946Others₹2.5 CrOpen
03 Jul 2025101120161Hdfc Bank Limited₹1.5 CrSatisfied
23 May 2025101104542Hdfc Bank Limited₹2.5 CrSatisfied
24 May 2023100721350Others₹3 CrSatisfied

To see the full charge records of Genpharmasec Limited, buy the company report.

Total charge records: 9 View all charges

Deals & funding

Genpharmasec Limited has 48 deals on record (47 market trades, 1 funding round), with disclosed funding of ₹48.45 Cr; the latest was in August 2026.

Total deals
48
Market trades
47
Funding round
1
Disclosed funding
₹48.45 Cr

Deals on record (5 of 48)

To see the full deal history of Genpharmasec Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Genpharmasec Limited has 1 MSME Form 1 return on record for the period ending Sep 2019, listing 2 overdue payments to 1 micro and small supplier. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (1 of 1)

SupplierAmount dueDue sinceReported on
Satellite Corporate Services P Ltd

To see the full MSME payment records of Genpharmasec Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

GST

Genpharmasec has 2 GST registrations: 1 active and 1 cancelled or inactive.

Total GSTINs
2
Active
1
Cancelled / inactive
1
GSTINStateStatusRegistered on
27AABCA8318D2ZXMaharashtraActive11 Nov 2017

To see the full GST registrations and return filing status of Genpharmasec Limited, buy the company report.

Recent activity

Genpharmasec Limited has 23 board changes on record since 2012: 7 appointments and 16 cessations. The latest: Sohan Chaturvedi was appointed as Whole-Time Director on 26 Apr 2024.

Filing
Genpharmasec Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 10.00 Cr with Charge ID 101210453 was registered on 20 Dec 2025.
Charges
A charge registered on 24 May 2023 via Charge ID 100721350 with Others was fully satisfied on 17 Dec 2025.
Charges
A charge registered on 03 Jul 2025 via Charge ID 101120161 with Hdfc Bank Limited was fully satisfied on 04 Dec 2025.
Charges
A charge registered on 23 May 2025 via Charge ID 101104542 with Hdfc Bank Limited was fully satisfied on 04 Dec 2025.
AGM
Genpharmasec Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 1.50 Cr with Charge ID 101120161 was registered on 03 Jul 2025.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 2.50 Cr with Charge ID 101104542 was registered on 23 May 2025.
Charges
A charge with Others amounted to Rs. 2.50 Cr with Charge ID 101108946 was registered on 06 May 2025.
Appointed
Sohan Chaturvedi was appointed as Whole-Time Director.
Appointed
Hardik Pravinbhai Makwana was appointed as Company Secretary.
Ceased
Heta Viraj Shah ceased to be Company Secretary.

34 earlier events are in the company report.

Frequently asked questions

Genpharmasec is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 16 November 1992 (34+ years old) and is registered under CIN L24231MH1992PLC323914. Listed on BSE: 531592.

Genpharmasec reported revenue of ₹139.94 Cr for FY 2025-26 (up 315% YoY) based on consolidated financials.

Genpharmasec has 7 current directors and KMP:

The latest financial statements of Genpharmasec on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Genpharmasec is 27AABCA8318D2ZX, registered in Maharashtra. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.

The CIN (Corporate Identification Number) of Genpharmasec is L24231MH1992PLC323914. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Genpharmasec is a listed company as per MCA records. Its shares are listed on BSE (code: 531592).

Genpharmasec has 6 court cases on record: 1 filed by the company and 5 filed against it. Most are in the district courts.

Genpharmasec was incorporated on 16 November 1992, making it 34+ years old. It is registered with the Registrar of Companies, Mumbai.

Genpharmasec has 48 deals on record (47 market trades, 1 funding round), with disclosed funding of ₹48.45 Cr; the latest was in August 2026.

The peers of Genpharmasec by revenue are Imaging Products (India) Private Limited, Nexnos Pharma Limited, Mamta Hygiene Products Private Limited, all in the BFSI industry (Broking Services, Healthcare Equipment Retail and Distribution), with the same principal business activity (wholesale trading).

Sohan Chaturvedi was appointed as Whole-Time Director on 26 Apr 2024. Hardik Pravinbhai Makwana was appointed as Company Secretary on 27 Mar 2024. Heta Viraj Shah ceased to be Company Secretary on 20 Mar 2024. Genpharmasec has 23 board changes on record in total.